Thus, there is potential application of LOX inhibitors in clinical trials to facilitate permeability of drugs and infiltration by tumor-killing immune cells39, taking into consideration that LOX inhibitors can only reduce the further crosslinking of collagen fibers, but not restore the already cross-linked ECM. The gene discussed is LOX; the disease is neoplasm.